American Journal of Clinical Oncology-Cancer Clinical Trials最新文献

{"title":"Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy: A Review of Literature.","authors":"Imed Taleb, Sarah Witmeyer, Hélène Charitansky, Sophie Auriol, Camille Chakiba, Nathalie Quenel Tueux, Adeline Petit, Benoite Méry, Wafa Bouleftour, Nicolas Magné","doi":"10.1097/COC.0000000000001194","DOIUrl":"https://doi.org/10.1097/COC.0000000000001194","url":null,"abstract":"<p><strong>Objectives: </strong>Adenoid cystic carcinoma (ACC) of the breast is a rare special histologic type of breast cancer. This tumor is classified as low-grade and has a favorable prognosis, with rare occurrence of metastasis and distinctive characteristics. Due to the uncommon nature of this tumor, there are no specific recommendations regarding the therapeutic management of this malignancy. The aim of this review was to provide an overview of breast ACC clinical characteristics with a special focus on radiotherapy management.</p><p><strong>Methods: </strong>A literature review was conducted up to January 2024 through a PubMed search using different combinations of pertinent keywords (eg, Adenoid cystic carcinoma alone, Adenoid cystic carcinoma AND breast Cancer AND radiotherapy; Adenoid cystic carcinoma AND breast cancer AND radiation therapy).</p><p><strong>Results: </strong>This review highlighted the lack of prospective and randomized data guiding treatment algorithms for ACC. Four retrospective studies explored the impact of postoperative radiation and concluded that postoperative radiation contributes to improved survival.</p><p><strong>Conclusions: </strong>Thus, a consideration for radiotherapy indications in ACC of the breast could be further elucidated through prospective randomized studies.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors and Patterns of Recurrence in Vulvar Cancer.","authors":"Francesca De Maria, Francesco Raspagliesi, Vito Chiantera, Umberto Leone Roberti Maggiore, Simone Bruni, Camilla Valsecchi, Ilaria Cuccu, Valentina Chiappa, Fabio Ghezzi, Giovanni Scambia, Jvan Casarin, Giorgio Bogani","doi":"10.1097/COC.0000000000001200","DOIUrl":"https://doi.org/10.1097/COC.0000000000001200","url":null,"abstract":"<p><strong>Objective: </strong>To identify prognostic factors predicting recurrence in vulvar cancer patients undergoing surgery.</p><p><strong>Methods: </strong>We retrospectively evaluated data from consecutive patients with vulvar cancer treated between 2002 and 2024 in 2 Italian centers. Basic descriptive statistics and multivariable analysis were used to create predictive models for patient outcomes. Five-year disease-free survival (DFS) and overall survival (OS) were analyzed using a Cox proportional hazards model.</p><p><strong>Results: </strong>The study included 283 patients diagnosed with vulvar cancer (239 with squamous cell carcinoma). The most frequent stages were stage I (50.9%) and stage III (30.4%). After a median follow-up of 27 months, 91 (32.2%) recurrences were observed, of which 20% were local, 6% were regional, and 6% were distant. The five-year DFS and OS were 46% and 60%, respectively. Multivariate analysis identified the presence of positive lymph nodes (hazard ratio [HR]: 3.54, 95% confidence interval [CI]: 1.04-12.08), age (HR: 1.02, 95% CI: 1-1.04), FIGO stage II (HR: 3.12, 95% CI: 1.24-7.87), and FIGO stage IV (HR: 3.85, 95% CI: 1.19-12.43) as factors associated with worse DFS. Positive nodes (HR: 2.64, 95% CI: 1.2-5.8) and tumor diameter >4 cm (HR: 1.89, 95% CI: 1.05-3.42) were associated with OS. FIGO stage >I was predictive of regional and distant recurrences, but no factor was found to correlate with local recurrence.</p><p><strong>Conclusions: </strong>FIGO stage >I was predictive of regional and distant recurrences, while no factors influencing local recurrence were identified. Positive nodes, age, and FIGO stage >I correlated with DFS, whereas tumor diameter >4 cm and positive nodes influenced OS.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standard Versus Extended Pelvic Lymphadenectomy in Patients With Bladder Cancer: A Systematic Review and Meta-analysis.","authors":"Hunaina Aman, Muhammad Hamza, Asad Ramzan, Mariam Saqib, Zain Ul Abideen, Abdul Haseeb, Hira Habib, Aiza Bint-E-Shafqat, Abdul Azeez Umar Azad, Hira Waris, Mushood Ahmed, Muhammad Ayyan, Nouman Aziz","doi":"10.1097/COC.0000000000001206","DOIUrl":"https://doi.org/10.1097/COC.0000000000001206","url":null,"abstract":"<p><strong>Objectives: </strong>For decades, pelvic lymph node dissection (PLND) has been a critical component of radical cystectomy in patients with bladder cancer. Although its role in curative surgery for high-risk non-muscle-invasive and muscle-invasive cases is well-established, the therapeutic advantages of extended PLND remain a topic of ongoing debate.</p><p><strong>Methods: </strong>A comprehensive literature search of major bibliographic databases was performed from inception to November 2024. Studies comparing extended PLND (extended or super extended) with standard PLND were identified. Data for clinical outcomes was extracted and pooled estimates were calculated using a random effects model with RevMan 5.4.</p><p><strong>Results: </strong>A total of 11 studies (2 RCTs and 9 observational) were included reporting data for 4001 patients. The pooled analysis demonstrated that extended PLND was associated with significantly better recurrence-free survival (HR=0.67, 95% CI: 0.60-0.74). Standard PLND led to significantly higher 5-year recurrence rates (RR=1.44, 95% CI: 1.28-1.62) compared with the extended approach. The pooled estimates for disease-specific survival (HR=0.86, 95% CI: 0.62-1.19), overall survival (HR=0.99, 95% CI: 0.86-1.16), and complications remained comparable.</p><p><strong>Conclusions: </strong>Extended PLND can lead to favorable recurrence-free survival and 5-year recurrence rates. However, retrospective observational studies mainly drive the evidence, and additional RCTs are required to reach a definitive conclusion.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Race and Ethnicity on Location and Delivery of Palliative Radiotherapy.","authors":"Anthony K Heng, Ted Gooley, Simon S Lo, Jonathan T Yang, Erin F Gillespie, Lia M Halasz, Yolanda D Tseng","doi":"10.1097/COC.0000000000001202","DOIUrl":"https://doi.org/10.1097/COC.0000000000001202","url":null,"abstract":"<p><strong>Objectives: </strong>Among patients that underwent palliative RT (pRT) at a single institution, we evaluated whether differences exist across race and ethnicity in location of pRT consultation and delivery of pRT.</p><p><strong>Methods: </strong>This retrospective study included cancer patients aged 18 years or older who received pRT between 10/2021 and 10/2022. Logistic regression models were used to examine univariable (UVA) and multivariable (MVA) associations between race and pRT consult in the inpatient (vs. outpatient) setting. A subset analysis of quality metrics for pRT delivery was limited to patients who had outpatient consults for pain.</p><p><strong>Results: </strong>Four hundred forty patients underwent 548 pRT consults (104 inpatient and 444 outpatient) followed by a course of pRT. Most patients were male (58.2%), White non-Hispanic (WNH) (72.6%), and English-speaking (92.9%). On MVA adjusting for histology, language, and insurance type, consults for Black/African American (BAA) patients had 2.92 higher odds of being performed in the inpatient setting compared with consults for WNH patients (95% CI: 1.28-6.70, P=0.011), although the global P-value was P=0.217. Among 290 outpatient consults for painful lesions, no differences in time to pRT start (global P=0.84), number of prescribed fractions of RT (global P=0.94), or new prescriptions for opioids (global P=0.69) were noted by race and ethnicity.</p><p><strong>Conclusions: </strong>In this study, BAA race was associated with the location of pRT consultation, but no discernible differences were noted regarding the outpatient delivery of pRT for pain. These findings support the importance of inpatient pRT programs to ensure equitable access. More research is needed to understand barriers to outpatient consult.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice Patterns of Surveillance in Sentinel Lymph Node-Positive Malignant Melanoma​​​: An International Survey.","authors":"Paul Wong, Michael O'Leary, Kelly Mahuron, Hans F Schoellhammer, Moshe Faynsod, Benjamin Paz, Laleh G Melstrom","doi":"10.1097/COC.0000000000001196","DOIUrl":"https://doi.org/10.1097/COC.0000000000001196","url":null,"abstract":"<p><strong>Objectives: </strong>To understand surveillance practice patterns in melanoma patients with a positive sentinel lymph node (SLN) biopsy.</p><p><strong>Methods: </strong>A survey was designed, tested for item relevance, readability, and content validity, and subsequently distributed to melanoma surgeons through institutional emails and international societies.</p><p><strong>Results: </strong>Majority of the 59 respondents were <10 years from training (59.3%), in academia (74.1%), or dedicated >25% of their practice to melanoma (50.8%). Nearly all surgeons (98.3%) would not recommend complete lymph node dissection (CLND) for a 2 mm melanoma with nodal metastasis <1 mm. 79.7% of surgeons claim a significant role in determining the surveillance regimen, and most (57.6%) opt for a combination of nodal basin ultrasound and CT or PET/CT, while 39.0% follow with ultrasound only. No difference in surveillance modality was seen when stratifying time since training (≤10 vs. >10 y; P=0.798). However, for those who dedicate >25% of their practice to melanoma, significantly fewer surgeons report use of ultrasound only (>25%: 13.3% vs. ≤25%: 65.5%; P<0.001). Whereas 33.9% of surgeons state their surveillance strategy is agnostic to patient factors, others claim adherence to appointments (30.5%), distance from hospital (18.9%), and insurance (15.8%) shift their management. Breslow depth >4 mm (27.4%), ulceration (22.2%), and mapping to >1 basin (16.2%) are the most common reasons surgeons obtain cross-sectional imaging. Reasons that deter surgeons against ultrasound as the surveillance modality of choice include reproducibility/interpretation of the results (42.6%), patient preference (25.0%), and medical oncology preference (22.1%).</p><p><strong>Conclusions: </strong>Despite trials aimed to inform the management of SLN-positive melanoma, surveillance strategies remain largely dependent on provider preference and individual patient factors.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives.","authors":"Binbin Chen, Qiongqiong Pan, Yuqing Dong","doi":"10.1097/COC.0000000000001197","DOIUrl":"https://doi.org/10.1097/COC.0000000000001197","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a malignant hematologic tumor of plasma cells that presents significant challenges in treatment and management. Despite the advent of novel therapies in recent years, which have improved patient outcomes, complete eradication of the disease remains an elusive goal. This underscores the critical need for in-depth research and ongoing innovation to tackle MM. Minimal residual disease (MRD) detection has emerged as a vital tool for evaluating treatment efficacy and predicting prognosis in MM patients, garnering extensive attention and application in recent years. This paper provides a comprehensive review of recent advancements in major MRD detection methods for MM patients, including multiparametric flow cytometry (MFC), allele-specific oligonucleotide real-time quantitative PCR (ASO-qPCR), and next-generation sequencing (NGS). It delves into the clinical applications of MRD detection, anticipates future developments, and offers valuable insights for improving diagnostic and therapeutic strategies. Through persistent research and innovation, we hope to bring better therapeutic prospects to MM patients.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Pegylated Filgrastim as Primary Prophylaxis Following Pediatric Dose-intensive Chemotherapy: A Randomized Controlled Trial.","authors":"Meena Haldorai, Jagdish P Meena, Aditya K Gupta, Ravindra M Pandey, Anita Chopra, Rachna Seth","doi":"10.1097/COC.0000000000001199","DOIUrl":"https://doi.org/10.1097/COC.0000000000001199","url":null,"abstract":"<p><strong>Objectives: </strong>Large trials and meta-analyses in adults suggest a similar efficacy and safety of a single dose of peg-filgrastim compared with daily filgrastim in the prevention of chemotherapy-induced neutropenia. However, there is no large prospective data in the pediatric population. This trial was designed to demonstrate the efficacy and safety of peg-filgrastim in children.</p><p><strong>Methods: </strong>This was an open-labelled randomized trial. Children with solid tumors receiving chemotherapy in which growth factor support was indicated were screened before chemotherapy and randomized to either the filgrastim arm (5 mcg/kg daily) or peg-filgrastim arm (100 mcg/kg single dose 24 h postchemotherapy). Patients were followed up till absolute neutrophil count (ANC) recovery clinically as well as by thrice weekly complete blood counts. The primary outcome was the incidence of FN, and secondary outcomes included the reduction in the depth of ANC nadir, shortening of the duration of grade-4 neutropenia, reduction in ANC recovery time, and adverse events.</p><p><strong>Results: </strong>A total of 344 chemotherapy cycles were screened. After the exclusion of 29 cycles, 315 chemotherapy cycles in 61 patients were randomized to peg-filgrastim (n=160) and filgrastim arm (n=155). The median age of included patients was 3 years (2; 6.5), and males were predominant. The incidence of FN in peg-filgrastim and filgrastim arms was 8% and 18% (P=0.01) (RR: 0.45; 95% CI: 0.24-0.84). Duration of ANC recovery, depth of ANC nadir, and adverse events reported were not significantly different in both arms.</p><p><strong>Conclusions: </strong>The incidence of FN in the peg-filgrastim arm was significantly lesser. No significant adverse events attributable to the study drug were reported.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Clinic: A Social Media Network Analysis of 5466 Posts Reveals the Interconnected Challenges Facing Sarcoma Patients.","authors":"Daniel Schneider, Ethan D L Brown, Jacob Gluski, Akash Mishra, Daniel M Sciubba, Sheng-Fu L Lo","doi":"10.1097/COC.0000000000001191","DOIUrl":"https://doi.org/10.1097/COC.0000000000001191","url":null,"abstract":"<p><strong>Objectives: </strong>Social media platforms have increasingly been investigated as a source of patient perspectives that may not emerge in clinical settings. This study aimed to explore how disease status, treatment, and the patient experience interconnect for sarcoma patients posting on a major social media platform.</p><p><strong>Methods: </strong>We conducted a systematic thematic analysis of 5466 posts across 7 health-related subreddits using a framework of 6 major categories: physical symptoms, disease status, treatments, psychosocial impact, support systems, and daily life impact. Theme detection utilized regular expression matching across 27 subthemes, while VADER sentiment analysis assessed emotional valence. The statistical analysis examined theme co-occurrences using Fisher exact tests and sentiment patterns using Mann-Whitney U tests.</p><p><strong>Results: </strong>Treatment-related discussions dominated the discourse, with chemotherapy (65.6%) and radiation therapy (60.2%) strongly associated with work-related impacts (OR=2.85 and 2.47, respectively; all OR P<0.001). Financial discussions and work-related posts demonstrated the highest user engagement. Disease progression was a critical transition point, demonstrating robust relationships with treatment modalities (chemotherapy: OR=3.12; radiation: OR=4.09), anxiety (OR=2.23), and uncertainty (OR=2.13). Support-seeking behavior (34.9%) was positively associated with medical team interactions (OR=2.16). Physical symptoms exhibited negative sentiment (-0.331±0.154), particularly discussions of weakness (-0.589) and breathing difficulties (-0.308). Hope-related discussions showed more positive sentiment than other psychosocial themes (Cohen d=-0.595, P<0.001).</p><p><strong>Conclusions: </strong>This network analysis reveals critical intersections between treatment decisions, financial concerns, and work impact within sarcoma care. Integrated support interventions that address both clinical and practical challenges-particularly treatment transitions and financial toxicity-may improve patient care.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Death From Infection Among Patients Living With Cancer.","authors":"Mckenzee Chiam, Kyle Mani, Xi Wang, Ming Wang, Daniel M Trifiletti, Leslie J Parent, Daniel E Spratt, Leila Tchelebi, Nicholas G Zaorsky","doi":"10.1097/COC.0000000000001182","DOIUrl":"https://doi.org/10.1097/COC.0000000000001182","url":null,"abstract":"<p><strong>Objectives: </strong>Early identification of patients living with cancer at higher risk of death from an infection is critical in infection mortality prevention. We characterize patients living with cancer at the highest risk of dying from an infection.</p><p><strong>Methods: </strong>7,529,481 US cancer survivors (1992 to 2015) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Standardized mortality ratios (SMRs) and 95% CIs were calculated. Fine-gray survival analysis was performed to calculate hazard ratios by adjusting for the effects of competing risks (eg, deaths due to causes other than infection).</p><p><strong>Results: </strong>Among 7,529,481 patients living with cancer (1992 to 2015), 101,167 (1.3%) died of infection. The rate of infection-specific mortality was 27.19/10,000 person-years, with an SMR of 3.29 (95% CI: 3.26-3.32, P<0.001). Patients who were older, male, black, and unmarried were at a greater risk of fatal infection. Overall, the risk of infection-specific mortality for patients living with cancer is greatest 1 year after diagnosis compared with the general population (SMR: 8.68, 95% CI: 8.53-8.84; P<0.0001), and this risk decreases with follow-up time (SMR at >10 y after diagnosis: 2.93, 95% CI: 2.87-3.00; P<0.0001). Among patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Kaposi Sarcoma, 9.2%, 11.5%, and 82.2% of all deaths within the first year after cancer diagnosis occurred due to acute infectious disease. In contrast, for patients with liver cancer, the relative percentage of infection-specific mortality increases with follow-up time from 3.5% at <1 year after cancer diagnosis and 10.4% at 10+ years of follow-up.</p><p><strong>Conclusion: </strong>The results of this study characterize infection mortality in patients living with cancer, which can guide more targeted research and interventions in this population.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer.","authors":"Pierre Loap, Salma Chabli, Paul Cottu, Youlia Kirova","doi":"10.1097/COC.0000000000001195","DOIUrl":"https://doi.org/10.1097/COC.0000000000001195","url":null,"abstract":"<p><strong>Objectives: </strong>Sacituzumab govitecan, an anti-TROP2 antibody-drug conjugate, is approved for metastatic triple-negative breast cancer (TNBC) from the second-line setting and for hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer from the third line. Radiotherapy is frequently required in metastatic settings for symptom control, but its combination with sacituzumab govitecan has not been formally evaluated. This study aims to assess the safety and tolerability of concurrent sacituzumab govitecan and radiotherapy in metastatic breast cancer patients.</p><p><strong>Methods: </strong>This retrospective, single-center study included all metastatic breast cancer patients who received sacituzumab govitecan and underwent external beam radiotherapy (EBRT) at Institut Curie. Clinical and pathologic data, treatment details, toxicities graded per CTCAE v5.0, and survival outcomes were analyzed. Overall survival (OS) was estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Thirteen patients were included, with a mean age of 54 years. The majority (61.5%) had TNBC. A total of 19 metastatic sites were irradiated, including 10 brain and 9 bone metastases. No radiation-induced toxicity was observed, and no patients required treatment interruption. Grade 3 to 4 toxicities were limited to neutropenia (15.4%). The median OS from radiotherapy completion was 6 months, with a 6-month OS rate of 45.1% and a 12-month OS rate of 16.9%.</p><p><strong>Conclusions: </strong>The concurrent administration of sacituzumab govitecan and radiotherapy appears well tolerated, with no increased toxicity. This combination may be feasible in metastatic breast cancer patients when clinically indicated. Further studies with larger cohorts are necessary to confirm these findings.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}